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Abeta oligomer-mediated long-term potentiation
impairment involves protein phosphatase 1-dependent
mechanisms
Abstract
Amyloid beta (Abeta) oligomers are derived from proteolytic cleavage of amyloid precursor
protein (APP) and can impair memory and hippocampal long-term potentiation (LTP) in vivo
and in vitro. They are recognized as the primary neurotoxic agents in Alzheimer's disease. The
mechanisms underlying such toxicity on synaptic functions are complex and not fully
understood. Here, we provide the first evidence that these mechanisms involve protein
phosphatase 1 (PP1). Using a novel transgenic mouse model expressing human APP with the
Swedish and Arctic mutations that render Abeta more prone to form oligomers (arcAbeta
mice), we show that the LTP impairment induced by Abeta oligomers can be fully reversed by
PP1 inhibition in vitro. We further demonstrate that the genetic inhibition of endogenous PP1
in vivo confers resistance to Abeta oligomer-mediated toxicity and preserves LTP. Overall,
these results reveal that PP1 is a key player in the mechanisms of AD pathology.
Brief Communications
A Oligomer-Mediated Long-Term Potentiation Impairment
Involves Protein Phosphatase 1-Dependent Mechanisms
Marlen Knobloch,1* Me´lissa Farinelli,2* Uwe Konietzko,1 Roger M. Nitsch,1‡ and Isabelle M. Mansuy2‡
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Amyloid  (A) oligomers are derived from proteolytic cleavage of amyloid precursor protein (APP) and can impair memory and
hippocampal long-term potentiation (LTP) in vivo and in vitro. They are recognized as the primary neurotoxic agents in Alzheimer’s
disease. Themechanisms underlying such toxicity on synaptic functions are complex andnot fully understood.Here, we provide the first
evidence that thesemechanisms involveproteinphosphatase 1 (PP1).Using anovel transgenicmousemodel expressinghumanAPPwith
the Swedish andArcticmutations that renderAmoreprone to formoligomers (arcAmice),we show that theLTP impairment induced
by A oligomers can be fully reversed by PP1 inhibition in vitro. We further demonstrate that the genetic inhibition of endogenous PP1
in vivo confers resistance to A oligomer-mediated toxicity and preserves LTP. Overall, these results reveal that PP1 is a key player in the
mechanisms of AD pathology.
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Introduction
Recent progress in the field of Alzheimer’s disease (AD) has pro-
vided evidence that amyloid  (A) oligomers rather than
-amyloid plaques are the major toxic agents in the pathology of
the disease (Selkoe, 2002). A oligomers have been demonstrated
to disrupt synaptic plasticity and impair memory (Lambert et al.,
1998;Walsh et al., 2002; Oddo et al., 2003; Lesne et al., 2006) and
are known to accumulate in the brain of AD patients (Takahashi
et al., 2002). Therapeutic strategies developed to interfere with
A deposition and clearance have shown initial benefit in AD
patients and rodent models (Hock et al., 2003; Klyubin et al.,
2005; Schenk et al., 2005). Neutralization of A toxicity, for in-
stance, was found to reversememory deficits in amousemodel of
ADwithout altering -amyloid plaque load (Dodart et al., 2002).
Many studies have attempted to determine the mechanisms
by which A assemblies disrupt synaptic plasticity and mediate
their detrimental effect, but the actual pathways that couple A
toxicity to synaptic functions remain only partially understood. A
recently identified mechanism implicates specific interactions
between A and neurotransmitter receptors such as the NMDA
(Snyder et al., 2005; Kelly and Ferreira, 2006) and -7 nicotinic
acetylcholine receptors (Oddo and LaFerla, 2006). This mecha-
nism was shown to recruit the Ca2-dependent protein phos-
phatase calcineurin (PP2B) (Chen et al., 2002; Snyder et al., 2005;
Kelly and Ferreira, 2006), a finding in line with the hypothesis
that Ca2 signaling is disrupted by A neurotoxicity (Demuro et
al., 2005).
To investigate whether othermajor signaling pathways down-
stream of the NMDA receptor are implicated in the mechanisms
of A toxicity in vivo, we generated a transgenic mouse model
expressing a human amyloid precursor protein (APP) with the
Swedish andArcticmutations (arcAmice) that produces a form
of Amore prone to yield A oligomers (Knobloch et al., 2007).
In these mice, expression of the mutant APP induces punctate
intraneuronal A deposition in several brain areas and severe
behavioral deficits before the onset of extracellular -amyloid
plaque deposition. Using this model, we show here that the over-
production of Arctic A is associated with an age-dependent
impairment in hippocampal long-term potentiation (LTP) and
synaptic plasticity in vitro that involves protein phosphatase 1
(PP1)-dependent mechanisms. Furthermore, we demonstrate
that both the pharmacologic and genetic inhibition of PP1 in vitro
and in vivo reverse the defect in synaptic plasticity induced by A
oligomers. These results strongly support a major role for PP1 in
the mechanisms of A oligomer-mediated toxicity and demon-
strate its reversibility in adult animals.
Materials andMethods
Animals. ArcA mice, APPSwe/PS1 mice, and I-1* mutant mice were
obtained by breeding as described previously (Holcomb et al., 1998;
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Genoux et al., 2002; Michalon et al., 2005; Knobloch et al., 2007). ArcA
mice express human APP 695 carrying both the Swedish (K670N;
M671L) and the Arctic (E693G) mutations in a single construct under
the control of the prion protein promoter. APPSwe/PS1 mice carry a
human APP with the Swedish mutation and a mutant presenilin 1
(M146L). I-1* mutant mice carry a transgene expressing an rtTA2 factor
under the control of the calcium/calmodulin-dependent kinase II 
(CaMKII) promoter and a transgene carrying a tetO promoter fused to
I1* cDNA. Mice were kept under standard housing conditions on a re-
versed 12 h light/dark cycle with food andwater ad libitum. Seven to nine
days before the experiments, I-1* mutant mice and control littermates
(carrying only the tetO-I-1* transgene) were fed doxycycline (West-
Ward Pharmaceuticals, Eatontown, NJ) at 6 mg/g of food. All animal
experiments were performed in accordance with guidelines of the Swiss
veterinary cantonal office (licenses Nr 150/06 and 123/04).
Electrophysiological recordings.Mice were anesthetized with isoflurane
and then decapitated. Heads were immediately immersed in ice-cold
freshly prepared artificial CSF (aCSF) for at least 2 min before brain
extraction. Acute slices (400 m thick) were prepared with a vibratome
(VT 1000S; Leica Microsystems, Bannockburn, IL) in ice-cold gassed
aCSF. Sections were incubated in aCSF at 34°C for 20 min and then kept
at room temperature for at least 1 h before recording. Recording was
performed in an interface chamber continuously flowed with aCSF at 1.1
ml/min. A monopolar electrode was placed in the Schaffer collaterals,
and stimulation was applied at 0.033 Hz with stimulus intensity ranging
from 20 to 80 A, yielding evoked field EPSPs (fEPSPs) of 0.2–0.5 V.
fEPSPs were recorded in the stratum radiatum using a borosilicate mi-
cropipette filled with aCSF. The signal was amplified with an Axopatch
200B amplifier (Molecular Devices, Union City, CA), digitized by a Digi-
data 1200 interface (Molecular Devices) and sampled at 10 kHz with
Clampex 8.2 (Molecular Devices). aCSF was composed of the following
(in mM): 119 NaCl, 11 D-glucose, 1.3 MgCl2.6H2O, 1.3 NaH2PO4, 2.5
KCl, 2.5 CaCl2, 26NaHCO3, gassed withO2/CO2 (95/5%) at least 20min
before use and throughout the experiment. Baseline was recorded for a
minimum of 20 min or until stable. Plasticity was then induced by stim-
ulation with either 1 Hz for 15 min (900 pulses), 2 Hz for 10 min (1200
pulses), 5 Hz for 3 min (900 pulses), 10 Hz for 1.5 min (900 pulses), or
100Hz for three trains of 1 s tetanus separated by 20 s.Datawere analyzed
by measuring the slope of individual fEPSPs at 1–1.5 ms after the stimu-
lus pulse by linear fitting using Clampfit (Molecular Devices). The
frequency-dependent plasticity curve (BCM curve) was built by deter-
mining mean fEPSP slopes over 10 min starting 35 min after stimulation
(according to Jouvenceau et al., 2006).
Reverse transcription and quantitative real-time PCR. Total RNA was
isolated from frozen hippocampi of 6-month-old arcAmice and wild-
type littermates (n 5 for each) with TRIzol (Invitrogen, Carlsbad, CA)
and cleaned up with RNeasy Mini kit (Qiagen, Valencia, CA). First-
strand cDNAwas synthesized using the SuperScript First-Strand Synthe-
sis System for RT-PCR (Invitrogen) according to the manufacturer’s
protocol. Real-time PCR was performed on TaqMan (ABI PRISM 7700
SDS) using SYBR Green (Applied Biosystems, Foster City, CA). Primer
sequences were as follows: NMDA receptor subunit 2B (NR2B) forward
(for.), AAGACAAGGGCCGATTCATG; reverse (rev.), GCAAAG-
GAGCTCTCACCAGC; CaMKII for., AGTCAGAGGAGACCCGCGT;
rev., TGTGGAAGTGGACGATCTGC; glutamate receptor 1 (GluR1)
for., CAATGTGGCAGGCGTGTTC; rev., TCGATTAAGGCAACCAG-
CATG; Syn.physin for., AAGGTGCTGCAGTGGGTCTTT; rev.,
CGAAGCTCTCCGGTGTAGCT; Zif268 for., CGAGAAGCCTTTTGC-
CTGTG; rev., TGGTATGCCTCTTGCGTTCA; Arc for., TGGAGG-
GAGGTCTTCTACCGT; rev., TATTTGCCGCCCATGGACT;-actin for.,
TACTCTGTGTGGATCGGTGGC; rev., TGCTGATCCACATCTGCTGG;
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for., GGCATCTT-
GGGCTACACTGAG; rev., CGAAGGTGGAAGAGTGGGAG.
Data analysis was performed according to the Ct method, normal-
ized to -actin and GAPDH. Statistical analysis was performed on the
Ct values using Student’s t test.
Passive immunization.Three-month-old arcAmice were immunized
with a single intraperitoneal injection (10 mg/kg) of either purified 6E10
(Signet, Dedham,MA) or negative control antibody formouse IgG1 (Lab
Vision, Fremont, CA) 48 h before slice preparation.
Tautomycin application. Slices from 3-month-old arcA mice, wild-
type littermates, and APPSwe/PS1 mice were bathed in normal aCSF or
aCSF containing 1 nM tautomycin (Sigma, St. Louis, MO) for at least 1 h
before recording.
PP1 activity assay.Activity of recombinant PP1 (New England Biolabs,
Beverly, MA) and calcineurin (Biomol, Plymouth Meeting, PA) was
measured with and without 1 nM tautomycin using a modified Biomol
Green Assay kit (Biomol).
Western blot analysis of phospho-CaMKII levels. Mice were perfused
transcardially with ice-cold PBS, and hippocampi were dissected and
immediately frozen in dry ice. Crude synaptic membrane fractions were
prepared according to Genoux et al. (2002). Equal amount of proteins
was loaded and separated by SDS-PAGE, transferred to a nitrocellulose
membrane, and blocked in TBS containing 1% BSA and 0.1% Triton
X-100. Primary antibodies [anti-phospho-CaMKII antibody, 1:1000
(Millipore, Billerica, MA); anti-total CaMKII antibody, 1:10,000 (Milli-
pore); and anti--actin antibody, 1:5000 (Abcam, Cambridge, MA)]
were incubated overnight at 4°C, and the corresponding secondary anti-
bodies were incubated for 1.5 h at room temperature. Commercial ECL
(GE Healthcare, Piscataway, NJ) was used for the detection of chemilu-
minescence. Densitometric analysis was performed using the free down-
loadable ImageJ software (http://rsb.info.nih.gov/ij/).
A oligomer preparation and application. A oligomers were prepared
according to Klein (2002). Synthetic A1–42 (Bachem, King of Prussia,
PA) was dissolved in Hexafluor2-propanol (HFIP), aliquoted, and kept
at80°C after evaporation of HFIP. A oligomers were prepared freshly
by dissolving the above peptide filmwith DMSO and diluting it into cold
F12 medium without phenol red to yield a 100 M stock. This prepara-
tion was incubated at 4°C for 24 h and centrifuged at 14,000  g for 10
min at 4°C, and the supernatant was further used for electrophysiological
experiments according to Wang et al. (2002). Slices were bathed for at
least 1 h in aCSF containing either A oligomers (1:200 diluted) or, as a
control, phenol red-free F12 medium only (1:200 diluted). To prevent a
washout of A oligomers during recording, the aCSF used for perfusion
contained a 1:400 dilution of A oligomers/phenol red-free F12, respec-
tively. Each A oligomer preparation was used for one I-1* mutant
mouse and a corresponding control in parallel, measured in a blinded
manner.
Electronmicroscopy.TheAoligomer preparationwas controlled by elec-
tron microscopy. Five microliters of the above supernatant were adsorbed
onto glow-discharged, 300-mesh carbon-coated Formvar grids for 2–3min,
negatively stainedwith 2%phosphorwolfram acid for 45 s, and viewedwith
a Philips CM12 scanning transmission electronmicroscope.
Results
Severe impairment in synaptic plasticity in arcAmice
To evaluate the effect of arcA on synaptic plasticity, we first
measured hippocampal LTP in area CA1 in vitro by recording
fEPSPs in acute slices from adult arcA mice and wild-type lit-
termates after 100 Hz stimulation. LTP was severely impaired in
slices from 3.5- and 7.5-month-old arcAmice (Fig. 1A,B) ( p
0.001; repeated-measurement ANOVA), with fEPSPs returning
to baseline within 10 min after LTP induction. The LTP deficit
was not caused by impaired synaptic transmission, because basal
transmission was normal in the transgenic slices (Fig. 1A,B, in-
set). It did not result from a developmental defect caused by
transgene expression either, because both LTP (Fig. 1C) and basal
synaptic transmission (Fig. 1C, inset) were normal in slices from
1-month-oldmice, consistent with the fact that A accumulation
is not detectable at this age despite high expression of mutant
APP (Knobloch et al., 2007). We confirmed that the LTP deficit
was caused by A oligomers by showing that it could be reversed
with a single dose of an antibody directed against theA sequence
(6E10) administered to the animals 48 h before LTP induction
(supplemental Fig. 1, available at www.jneurosci.org as supple-
Knobloch et al. • PP1 Is Involved in A-Mediated LTP Impairment J. Neurosci., July 18, 2007 • 27(29):7648–7653 • 7649
mental material). The antibody treatment
restored LTP in transgenic slices to85%
level of potentiation compared with slices
fromwild-type littermates. A control anti-
body of the identical IgG class against a
nonrelated antigen failed to rescue LTP
(supplemental Fig. 1, available at www.j-
neurosci.org as supplemental material). In
addition to a deficit in plasticity at high
induction frequency (100 Hz for LTP),
stimulation frequencies of 5 and 10Hz also
showed reduced fEPSP potentiation in
slices from arcA mice compared with
wild-type slices. Plasticity at 1 or 2 Hz
stimulation frequency was not changed
(Fig. 2D). These results reveal a deficit in
plasticity across a wide range of stimula-
tion frequencies with a shift of responses
toward synaptic depression.
To examine whether candidate genes
involved in synaptic signaling may under-
lie the impairment in plasticity induced by
A oligomers, we measured the level of
expression of several candidate genes by
real-time reverse transcription (RT)-PCR.
Hippocampal expression of synaptophy-
sin, a synaptic vesicle protein involved in
neurotransmitter release, the NR2B and
GluR1 subunits of the NMDA and AMPA
receptors critical for glutamatergic neuro-
transmission, or CaMKII, a major protein
kinase necessary for the induction of LTP
(Lisman et al., 2002), was not altered in
arcA mice (Fig. 1D). However, because
intracellular Ca2 signaling is altered by
A oligomers, it is likely that Ca2-dependent posttranslational
processes such as protein phosphorylation are perturbed. There-
fore, we examined whether phosphorylation of CaMKII is
changed in arcAmice. Western blot analyses revealed a decrease
in the level of phosphorylatedCaMKII in synapticmembranes from
arcAmice (supplemental Fig. 2, available at www.jneurosci.org as
supplementalmaterial), suggesting aperturbation inprotein kinase/
phosphatasepathways.Furthermore, theexpressionof transcription
factors rapidlyactivatedafterneuronal activity andrequired forLTP,
arg3.1/arc andzif268 (Worley et al., 1991;Linket al., 1995;Guzowski
et al., 2000), was significantly reduced in arcAmice (Fig. 1D) [p
0.05; t test;mean and range percentage change versuswild type (wt):
arg3.1, 67%(58–78%); zif268, 52%(45–61%)].These results there-
fore indicate that A oligomers alter protein phosphorylation
and the activation of immediate early genes (IEGs).
In vitro inhibition of PP1 reverses A oligomer-mediated
plasticity impairment
Because PP1 is a major protein phosphatase in neurons that neg-
atively regulates intracellular signaling downstream from the
NMDA receptor (including CaMKII) and modulates hippocam-
pal LTP (Jouvenceau et al., 2006; Mansuy and Shenolikar, 2006),
we examined whether it might be involved in the deficit in plas-
ticity induced by A oligomers. PP1 was inhibited pharmacolog-
ically in acute hippocampal slices from arcAmice andwild-type
littermates using the selective inhibitor tautomycin (1 nM), and
the effect on plasticity was examined across several stimulation
frequencies. Remarkably, PP1 inhibition was found to fully re-
verse the deficit in plasticity observed at 5, 10, or 100Hz in arcA
slices (Fig. 2A,D) ( p  0.05; repeated-measurement ANOVA)
but had no effect on plasticity in wild-type slices (Fig. 2B) ( p 0.3;
repeated-measurement ANOVA). This rescuing effect resulted spe-
cifically from PP1 inhibition and did not involve the protein phos-
phatase calcineurin because only PP1 activity was significantly
inhibited by 1 nM tautomycin (Fig. 2C), confirming that PP1-
dependent mechanisms are involved in the plasticity deficit.
To confirm the rescuing effect of PP1 inhibition observed in
arcA mice, we examined whether it could be reproduced in
another transgenicmousemodel of AD.We tested the well estab-
lished APPSwe/PS1 model that expresses human APP carrying
the Swedish mutation and a mutated Presenilin1 and exhibits an
early AD pathology associated with marked behavioral deficits
(Holcomb et al., 1998). Similarly to arcAmice, CA1 hippocam-
pal LTP was severely impaired in 3-month-old APPSwe/PS1 an-
imals and was significantly rescued by PP1 inhibition (1 nM tau-
tomycin) (Fig. 2E) ( p 0.05; repeated-measurement ANOVA).
The rescue was however less pronounced than in arcA mice,
possibly because of higher production of themore toxic A1–42 as
a result of the presenilin mutation in APPSwe/PS1. Together,
these results strongly suggest that PP1 is a critical factor in the
course of A-mediated toxicity.
Inhibition of endogenous PP1 in vivo confers resistance to
A oligomer-mediated toxicity
To assess whether the detrimental effect of PP1 is also reversible
in vivo, we examined whether inhibition of endogenous PP1 be-
Figure 1. CA1 hippocampal LTP is impaired in arcAmice. A, B, CA1 hippocampal LTP is severely impaired in slices from 3.5-
and 7.5-month-old arcAmice (n 5 tg, 5wtmice) but basal transmission is normal (right inset). C, LTP and basal transmission
(right inset) are normal in slices from1-month-old arcAmice (n 5 tg, 5wtmice). Left insets, Individual fEPSP traces for tg and
wtmice before (black) and after (red) LTP induction. Calibration:A,B, 0.4mV, 5ms; C, 0.6mV, 5ms.D, Real-time RT-PCR: normal
mRNA expression of synaptophysin, NMDAandAMPA receptors, and CaMKII, but reduced arg3.1 (67%; range, 58–78%; n 5 tg
and 5 wt mice) and zif268 (52%; range, 45–61%) expression in the hippocampus of 6-month-old arcA mice. Error bars
represent SEM. *p 0.05. norm., Normalized; Synapto., synaptophysin; Tg, transgenic.
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fore exposure toA oligomers confers resistance toA oligomer-
mediated toxicity. We took advantage of a transgenic mouse
model in which PP1 is selectively inhibited (by 40–60%) in fore-
brain neurons by expression of a constitutively active form of the
PP1 inhibitor-1 (I-1*) (Genoux et al., 2002; Michalon et al.,
2005). Acute slices from adult I-1* transgenic mice were exposed
to A oligomers produced from synthetic A1–42. This prepara-
tion of A oligomers contained globular A assemblies of 7–12
nm diameter (Fig. 3A), as previously described (Klein, 2002). To
verify that our preparation of A oligomers had the reported
inhibitory effect on LTP (Wang et al., 2002), we bathed slices
fromwild-typemice in aCSF containing A oligomers (0.5Mof
the initial peptide) or normal aCSF. As expected, A oligomers
strongly impaired the induction of LTP in slices from wild-type
mice, and fEPSPs returned to baseline within 10min after tetanic
stimulation (Fig. 3B). Likewise, A oligomers impaired LTP in
slices from I-1* control littermates (Fig. 3C) ( p 0.05; repeated-
measurement ANOVA). However, in slices from I-1* transgenic
mice, A oligomers did not prevent the induction of LTP, which
was robust and stable (Fig. 3D) ( p 0.6; repeated-measurement
ANOVA comparing LTPwith and without A oligomers). These
results therefore indicate that PP1 inhibition in vivo confers pro-
tection against A oligomer-mediated toxicity.
Discussion
This study demonstrates that the inhibitory effects of A oli-
gomers on hippocampal LTP in the adult brain are reversible and
that normal LTP can be restored by PP1 inhibition in vitro in
independentmousemodels of AD (arcAmice andAPPSwe/PS1
mice). It also reveals that in addition to
LTP induced by 100 Hz stimulation, A
oligomers perturb synaptic plasticity in the
hippocampus at intermediate frequencies
(5 and 10 Hz) and induce a general shift in
synaptic responses toward depression that,
similar to LTP, can be fully reversed by
PP1 inhibition. Endogenous PP1 inhibi-
tion in vivo is further shown to prevent the
impairment of LTP induced by A oli-
gomers, providing strong evidence that
PP1 is a critical player in the mechanisms
of A oligomer-mediated toxicity.
Although themechanisms of A action
are not fully understood, our results pro-
vide evidence that, in addition to involving
PP1-dependent processes, they also impli-
cate CaMKII and IEGs. CaMKII, arg3.1,
and zif268 are traditionally known as key
molecules in the mechanisms of LTP and
memory formation (Jones et al., 2001; Lis-
man et al., 2002; Tzingounis and Nicoll,
2006) and have also been implicated in
-amyloid pathology (Dickey et al., 2003;
Lin et al., 2004). The novel correlation that
our results reveal between these molecules
and PP1 suggests that they may be down-
stream targets of PP1-dependent pathways
perturbed by A oligomers. This may in-
volve direct dephosphorylation of
CaMKII by PP1, because CaMKII is a
known target of PP1 (Strack et al., 1997)
and could account for the alteration in
plasticity in our model, which is severe,
despite normal expression of NMDA and
AMPA receptors and synaptophysin. Interestingly, PP1 inhibi-
tion in vivo has been shown to increase CaMKII phosphorylation,
shift hippocampal plasticity toward potentiation (Jouvenceau et
al., 2006), and reverse cognitive deficits in aged mice (Genoux et
al., 2002). The present results significantly extend these previous
findings by demonstrating the relevance of these PP1-dependent
pathways in the mechanisms of AD. The present findings further
underscore the implication of dysfunctional protein phosphory-
lation in AD pathology and highlight the importance of protein
phosphatases in this pathology. The importance of their contri-
bution is clearly reflected by the fact that the deficits in plasticity
associated with the pathology are fully reversible, just like protein
phosphorylation is. Because PP1 is a major protein phosphatase
in neuronal cells, multiple targets and pathways are likely to be
modified, such as phosphorylation or trafficking of glutamate
receptors, as recently shown in primary neurons and organotypic
brain slices from ADmouse models (Snyder et al., 2005; Hsieh et
al., 2006).
Finally, the severe LTP impairment observed in young arcA
mice (3 months) when no -amyloid plaques are detectable sup-
ports the hypothesis that oligomeric A species are major con-
tributors to synaptic failure in AD (for review, see Rowan et al.,
2003). The rescue of LTP achieved with a single dose of an anti-
body directed against the A sequence confirms this hypothesis
and suggests that such antibodies may be useful in immunother-
apeutic strategies against AD (Rowan et al., 2005). In our model,
the reduced arg3.1 and zif268 expression occurs before any de-
tectable extracellular -amyloid deposition, supporting the evi-
Figure 2. In vitro inhibition of PP1 reverses A oligomer-mediated LTP impairment. A,B, PP1 is inhibited by bath application
of 1 nM tautomycin (tauto) in slices from 3-month-old arcAmice and wild-type littermates. Tautomycin fully reverses the LTP
deficit in slices from tgmice (n 5) but has no effect inwt (n 5mice). It also does not change basal transmission (right insets).
Left insets, Individual fEPSP traces for tg and wt mice before (black) and after (red) LTP induction. Calibration: 0.3 mV, 5 ms. C,
Phosphatase activity assays showing that 1 nM tautomycin specifically inhibits the activity of recombinant PP1 but not of recom-
binant calcineurin. D, Frequency–response curve showingmean fEPSP slopes over 10min starting 35min after stimulation with
1, 2, 5, 10, and 100 Hz in slices from tg andwtmice treated or not with tautomycin (n 3–5 slices per condition and frequency).
E, PP1 inhibitionwith 1 nM tautomycin also reverses the LTP deficit seen in 3-month-old APPSwe/PS1mice, anothermousemodel
of AD (n 5 tg). Error bars represent SEM. CN, Calcineurin; Tg, transgenic; w/o, without.
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dence that disruption of synaptic plasticity
is an early event in the course of the dis-
ease.Overall, these results point to PP1 as a
promising target for the development of
potential therapeutic approaches against
A-mediated toxicity in AD.
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